Given the limited availability of potent and selective HCAR3 modulators and the receptor’s critical role in lipid metabolism, this study was undertaken to identify novel ligands through an integrated CADD workflow, aiming to provide a rational foundation for developing targeted therapies against dyslipidemia and related metabolic disorders. The gene discussed is HCAR3; the disease is metabolic syndrome.